ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Complete and High-Resolution HLA Typing Improves the Accuracy of Post-Transplant Assessment of De Novo Anti-Donor Immune-Mediated Events

M. Meneghini1, A. Perona2, E. Crespo3, F. J. Bemelman4, P. M. Reinke5, O. Viklicky6, M. Giral7, O. Bestard1

1Vall d'Hebron University Hospital, Barcelona, Spain, 2Universitat de Barcelona, Barcelona, Spain, 3Nephrology and Transplantation Laboratory, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, 4Amsterdam University Medical Centers, Amsterdam, Netherlands, 5Charité Universitätsmedizin, Berlin, Germany, 6Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic, 7Nantes Université, Inserm, CHU Nantes, Nantes, France

Meeting: 2022 American Transplant Congress

Abstract number: 933

Keywords: Graft survival, Histocompatibility, Kidney transplantation, Rejection

Topic: Basic Science » Basic Science » 11 - Histocompatibility and Immunogenetics

Session Information

Session Name: Histocompatibility and Immunogenetics

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: High-resolution (HR) HLA typing using NGS technology has shown to improve the accuracy of assessing donor-recipient compatibility and characterization of pre-transplant anti HLA antibodies with donor- specificity. However, the impact of using complete and HR HLA typing after kidney transplantation (KT) to assess the advent of de novo DSA (dnDSA) and their impact on graft outcomes has not been thoroughly assessed.

*Methods: Multicentre, RCT, available DNA samples were re-evaluated for HR HLA typing using NGS technology at 6 HLA loci (A/B/C/DRB1/DQB1+A1/DPB1). De novo anti-HLA antibodies were assessed by solid phase assays, and dnDSA were classified either:1) as per current clinical practice according to uncomplete Low-resolution (LR) typing at 3 loci (A/B/DRB1), estimating donor C and DQ typing with publicly available frequency tables, or 2) according to complete 6 loci HR typing. The impact on graft outcomes was compared between groups. Mean follow up was 55±15.6 months.

*Results: Using LR HLA typing, 36(15%) patients developed dnDSA (LR_dnDSA+). Out of these, 29(80%) were confirmed to be dnDSA by HR typing (LR_dnDSA+/HR_dnDSA+), whereas 7(20%) were not (LR_dnDSA+/HR_dnDSA-). 3 additional patients were found to show dnDSA not detected by uncomplete LR typing (LR_dnDSA-/HR_dnDSA+).Out of a total of 59 DSA detected in 39 patients, 36(61%) were sconfirmed by both LR and HR HLA typing whereas in 15 cases(25%) LR specificity was not confirmed by HR HLA typing. Moreover, 8(14%) anti-HLA antibodies were identified to be DSA only by HR HLA typing.10/32 (31%) patients displayed class I dnDSA, 19 (59%) class II, and 3 (9%) both class I and II. When assessing main graft outcomes, LR_dnDSA+/HR_dnDSA+ patients were at higher risk of ABMR as compared to patients without dnDSA and LR_dnDSA+/HR_dnDSA- (log Rank<0.001), as well as higher risk of death-censored graft loss (log Rank<0.001). Both LR_dnDSA+ (HR 3.51, 95%CI 1.25-9.85) and LR_dnDSA+/HR_dnDSA+ (HR 4.09, 95%CI 1.45-11.54), but not LR_dnDSA+/HR_dnDSA- independently predicted graft loss together with previous transplants (HR 0.24, 95%CI 0.07-0.84), 12-months eGFR (HR 0.94, 95%CI 0.89-0.98), and previous acute rejection (HR 4.08, 95%CI 1.23-13.52).

*Conclusions: The implementation of HR HLA typing improves the characterization of biologically relevant anti-donor specificities of de novo anti-HLA antibodies and discriminates patients with poorer graft outcomes.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Meneghini M, Perona A, Crespo E, Bemelman FJ, Reinke PM, Viklicky O, Giral M, Bestard O. Complete and High-Resolution HLA Typing Improves the Accuracy of Post-Transplant Assessment of De Novo Anti-Donor Immune-Mediated Events [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/complete-and-high-resolution-hla-typing-improves-the-accuracy-of-post-transplant-assessment-of-de-novo-anti-donor-immune-mediated-events/. Accessed June 5, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences